WO2021136492A1 - 胃滞留片 - Google Patents

胃滞留片 Download PDF

Info

Publication number
WO2021136492A1
WO2021136492A1 PCT/CN2020/142069 CN2020142069W WO2021136492A1 WO 2021136492 A1 WO2021136492 A1 WO 2021136492A1 CN 2020142069 W CN2020142069 W CN 2020142069W WO 2021136492 A1 WO2021136492 A1 WO 2021136492A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
present disclosure
certain embodiments
polyvinyl alcohol
sustained
Prior art date
Application number
PCT/CN2020/142069
Other languages
English (en)
French (fr)
Inventor
李伟
潘阳
童伟勤
Original Assignee
广州玻思韬控释药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州玻思韬控释药业有限公司 filed Critical 广州玻思韬控释药业有限公司
Publication of WO2021136492A1 publication Critical patent/WO2021136492A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present disclosure generally relates to the field of medicine. More specifically, this application relates to the field of pharmaceutical preparations.
  • the gastric retention and release system utilizes the local pH of the gastrointestinal tract, gastrointestinal enzymes, the transport mechanism of the preparation in the gastrointestinal tract and other physiological characteristics, and changes the physical and chemical properties of the preparation to prolong the drug retention time in the stomach. system.
  • the present disclosure relates to a gastro-retentive tablet comprising a tablet core, a sustained-release layer, and an isolation layer between the tablet core and the sustained-release layer, wherein the tablet core contains a first active pharmaceutical ingredient and a swelling agent .
  • the present disclosure relates to a method for preparing a gastro-retentive tablet, which includes: preparing a tablet core containing a first active pharmaceutical ingredient and a swelling agent; coating the tablet core with an isolation layer to obtain a tablet with an isolation layer, And coating the tablet with the isolation layer with a sustained-release layer to obtain the gastric retention tablet.
  • the present disclosure relates to a gastric retention tablet, which is prepared by a method including the following steps: preparing a tablet core containing a first active pharmaceutical ingredient and an expanding agent; coating the tablet core with an isolation layer to obtain a tablet with isolation A layered tablet, and a sustained-release layer coating on the tablet with an isolation layer, thereby obtaining the gastric-retentive tablet.
  • the present disclosure relates to a method for improving the compliance of an individual, which comprises administering a gastric-retentive tablet to the individual in need of the method, wherein the gastric-retentive tablet comprises a tablet core, a sustained-release layer, and a tablet core. And the isolation layer between the sustained-release layer, wherein the tablet core contains the first active pharmaceutical ingredient and a swelling agent.
  • Figure 1 shows an electron micrograph (300 times magnification) of the metformin hydrochloride sustained-release tablet of Example 1 of the present disclosure after swelling.
  • Figure 2 shows an electron micrograph (500 times magnification) of the metformin hydrochloride sustained-release tablet of Example 1 of the present disclosure after expansion.
  • Fig. 3 shows an electron micrograph (300 times magnification) of the metformin hydrochloride sustained-release tablet of Example 2 of the present disclosure after swelling.
  • Figure 4 shows an electron micrograph (500 times magnification) of the metformin hydrochloride sustained-release tablet of Example 2 of the present disclosure after expansion.
  • Fig. 5 shows an electron micrograph (300 times magnification) of the metformin hydrochloride sustained-release tablet of Example 3 of the present disclosure after swelling.
  • Fig. 6 shows an electron micrograph (500 times magnification) of the metformin hydrochloride sustained-release tablet of Example 3 of the present disclosure after swelling.
  • Fig. 7 shows an electron micrograph (300 times magnification) of the metformin hydrochloride sustained-release tablet of Example 4 of the present disclosure after swelling.
  • Figure 8 shows an electron micrograph (500 times magnification) of the metformin hydrochloride sustained-release tablet of Example 4 of the present disclosure after swelling.
  • Fig. 9 shows the cumulative release curve of the metformin hydrochloride sustained-release tablets of Examples 1 to 4 of the present disclosure.
  • references to “one embodiment,” “an embodiment,” “in another embodiment,” or “in certain embodiments” throughout the specification mean that at least one embodiment includes the Related specific reference elements, structures or characteristics.
  • the appearances of the phrases “in one embodiment” or “in an embodiment” or “in another embodiment” or “in certain embodiments” in various places throughout the specification do not necessarily all refer to the same embodiment.
  • specific elements, structures, or characteristics may be combined in one or more embodiments in any suitable manner.
  • pharmaceutically acceptable salt includes “acceptable acid addition salt” and “acceptable base addition salt”.
  • the term "acceptable acid addition salt” refers to those salts that maintain the biological effectiveness and properties of the free base.
  • the acid addition salt is biologically or otherwise suitable and uses inorganic Acid or organic acid, the inorganic acid such as but not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc., the organic acid such as but not limited to acetic acid, 2,2-dichloroacetic acid, adipic acid , Alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzenecarboxylic acid, 4-acetamidobenzenecarboxylic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid , Citric acid, cyclohexane sulfamic acid, dodecyl sulfonic acid, ethane-1,2-d
  • the term "acceptable base addition salts” refers to those salts that maintain the biological effectiveness and properties of the free acid, and the base addition salts are biologically or otherwise suitable. These salts are prepared by adding inorganic or organic bases to the free acid. Salts derived from inorganic bases include but are not limited to sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. In certain embodiments, the inorganic salts are ammonium, sodium, potassium, calcium, and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and salts of basic ion exchange resins, such as ammonia, isopropylamine, Trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, Caffeine, procaine, hybamin, choline, betaine, benzylamine, phenylethylenediamine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, Purine, piperazine, piperidine, N-ethyl piperidine, polyamine resin, etc.
  • the organic base is is is is
  • active pharmaceutical ingredient refers to a chemical entity that can effectively treat the target disorder, disease or condition.
  • separation layer refers to a layer provided between the tablet core containing the active pharmaceutical ingredient and the sustained release layer to prevent the active pharmaceutical ingredient from interacting with the sustained release layer (ie, isolate).
  • expansion agent refers to an auxiliary material that can absorb moisture and expand in volume when placed in a water-containing environment.
  • the term "porogen” refers to water-soluble excipients dispersed in the polymer material of the sustained-release coating film, which dissolves when the tablet contacts an aqueous liquid, so that the sustained-release coating film has micropores and permeability .
  • binder refers to auxiliary materials that make the materials stick together and facilitate granulation.
  • the term "glidant” refers to an auxiliary material that reduces the friction between particles, thereby improving the fluidity of the powder.
  • lubricant refers to an auxiliary material that reduces the friction between particles, thereby improving the fluidity of the powder.
  • plasticizer refers to an excipient that has polarity or partial polarity in structure. It has the characteristics of high boiling point, hard to volatilize, and good miscibility with polymers. The plasticizer is distributed in large Between molecular chains, it can reduce the intermolecular force, reduce the viscosity of the polymer and increase the flexibility.
  • the term “sunscreen” refers to a substance that can absorb, scatter or reflect light.
  • the term "defoamer” refers to a substance that can reduce the surface tension of water, solution, suspension, etc., prevent the formation of foam, or reduce or eliminate the original foam.
  • surfactant refers to a substance that can significantly reduce the surface tension of a liquid.
  • aqueous medium refers to water or a liquid system using water as a solvent.
  • short diameter refers to the shortest diameter of the preparation retained in the stomach.
  • the term "compliance” refers to an individual who is treated according to the doctor's prescription, and his behavior is consistent with the doctor's order; otherwise, it is called non-compliance.
  • the present disclosure relates to a gastro-retentive tablet comprising a tablet core, a sustained-release layer, and an isolation layer between the tablet core and the sustained-release layer, wherein the tablet core contains a first active pharmaceutical ingredient and a swelling agent .
  • the sustained-release layer in the gastroretentive tablet of the present disclosure contains a mixture containing polyvinyl acetate and povidone.
  • the sustained-release layer in the gastric retention tablet of the present disclosure contains a polymer of ethyl acrylate and methyl methacrylate monomers.
  • the sustained-release layer in the gastric retention tablet of the present disclosure contains a polymer comprising a mixture of polyvinyl acetate and povidone and monomers of ethyl acrylate and methyl methacrylate.
  • illustrative examples of mixtures comprising polyvinyl acetate and povidone that can be used in the present disclosure include, but are not limited to SR.
  • illustrative examples of polymers of ethyl acrylate and methyl methacrylate monomers include, but are not limited to NE30D.
  • the weight ratio of the sustained-release layer of the gastroretentive tablet of the present disclosure comprising a mixture of polyvinyl acetate and povidone to a polymer of ethyl acrylate and methyl methacrylate monomers is about 1:20 to 20:1.
  • illustrative examples of the first active pharmaceutical ingredient that can be used in the present disclosure are selected from the group consisting of levodopa, methazine hydrochloride, diazepam, furanilide, captopril, succinic acid Metoprolol, rosiglitazone maleate, verapamil, atenolol, losartan, pentoxifylline, nimodipine, cinnarizine, diltiazem, piretanide, isosorbide dinitrate , Sotalol, propranolol, celilolol hydrochloride, cholestyramine, nifedipine, dipyridamole, quinidine gluconate, lovastatin, trimetazidine hydrochloride, nicardipine, Isosorbide mononitrate, metronidazole, clarithromycin, nitrofurantoin, ofloxacin
  • illustrative examples of the first active pharmaceutical ingredient include, but are not limited to, carbidopa and levodopa, levodopa and benserazide, pregabalin, metformin hydrochloride, Amoxicillin, Acyclovir and Gabapentin.
  • the release layer of the present disclosure comprises a water-soluble polymer.
  • illustrative examples of water-soluble polymers that can be used in the isolation layer of the present disclosure include, but are not limited to, sodium alginate, hypromellose, polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol Graft polymers and mixtures containing polyethylene glycol and polyvinyl alcohol.
  • illustrative examples of water-soluble polymers that can be used in the release layer of the present disclosure include, but are not limited to, polyvinyl alcohol-polyethylene glycol graft polymers.
  • polyvinyl alcohol-polyethylene glycol graft polymers that can be used in the present disclosure include, but are not limited to IR.
  • illustrative examples of mixtures comprising polyethylene glycol and polyvinyl alcohol that can be used in the present disclosure include, but are not limited to II.
  • the sustained release layer of the present disclosure includes a porogen.
  • illustrative examples of water-soluble polymers useful as porogens include, but are not limited to, sodium alginate, hypromellose, hydroxypropyl cellulose, povidone , Polyethylene glycol and polyvinyl alcohol-polyethylene glycol graft polymer.
  • illustrative examples of water-soluble polymers useful as porogens include, but are not limited to, hypromellose, hydroxypropyl cellulose, povidone, polyethylene glycol Alcohol and polyvinyl alcohol.
  • illustrative examples of water-soluble polymers that can be used in the present disclosure as porogens include, but are not limited to, a 2% solution with a viscosity of 3 mpa ⁇ s or more and 50 mpa ⁇ s or less at about 20°C.
  • Hypromellose a 2% solution of hydroxypropyl cellulose with a viscosity above 75mpa ⁇ s and below 3,000mpa ⁇ s at about 20°C
  • povidone K12, povidone K17, povidone K25, Povidone K30, povidone K90 polyethylene glycol with a molecular weight of 1,000 to 20,000, and polyvinyl alcohol-polyethylene glycol graft polymer.
  • illustrative examples of water-soluble polymers as porogens that can be used in the present disclosure include, but are not limited to, Methocel TM E3, Methocel TM E5, Methocel TM E6, Benecel TM E3, Benecel TM E5, Benecel TM E6 and IR.
  • the sustained release layer of the present disclosure includes a glidant.
  • illustrative examples of glidants that can be used in the tablet cores of the present disclosure include, but are not limited to, colloidal silica, micronized silica gel, polyethylene glycol, magnesium stearate, stearic acid , Talcum powder and starch.
  • the sustained release layer of the present disclosure includes a sunscreen agent.
  • sunscreens that can be used in the present disclosure include, but are not limited to, titanium dioxide and talc.
  • the sustained release layer of the present disclosure includes an antifoaming agent.
  • illustrative examples of defoamers that can be used in the present disclosure include, but are not limited to, simethicone and mixtures of simethicone and silicon dioxide.
  • the sustained release layer of the present disclosure includes a surfactant.
  • illustrative examples of surfactants that can be used in the present disclosure include, but are not limited to, gum arabic, xanthan gum, gelatin, propylene glycol monostearate, glyceryl monostearate, distearic acid Vinyl acid ester, monoglyceride diglyceride, sodium lauryl sulfate, Span 20, Span 40, Span 60, Span 65, Span 80, Span 83, Span 85, potassium oleate, sodium oleate, triethanolamine oil Ester, Lecithin, Sucrose Ester, Poloxamer 188, Atlas G-263, Tween 20, Tween 21, Tween 40, Tween 60, Tween 61, Tween 65, Tween 80, Tween 81, Tween 85, Myrj 45, Myrj 49, Myrj 51, Myrj 52, polyoxyethylene 400 monolaurate, polyoxyethylene 400 monostearate, polyoxyethylene 400 monooleate
  • the sustained release layer of the present disclosure includes a plasticizer.
  • plasticizers that can be used in the present disclosure include, but are not limited to, phthalic acid esters, aliphatic dibasic acid esters, phosphoric acid esters, epoxides, fatty acid esters, and polycarbonates. Ethylene glycol.
  • illustrative examples of phthalates that can be used in the present disclosure include, but are not limited to, dimethyl phthalate (DMP), diethyl phthalate (DEP), phthalate Dibutyl phthalate (DBP), dioctyl phthalate (DOP) and octyl phthalate (DnOP).
  • DMP dimethyl phthalate
  • DEP diethyl phthalate
  • DBP phthalate Dibutyl phthalate
  • DOP dioctyl phthalate
  • DnOP octyl phthalate
  • aliphatic dibasic acid esters that can be used in the present disclosure include, but are not limited to, bis(2-ethylhexyl) adipate (DOA), diisodecyl adipate Esters (DIDA), diazodiacid (2-ethylhexyl) (DOZ), diethylhexyl sebacate (DOS) and dibutyl sebacate (DBS).
  • DOA bis(2-ethylhexyl) adipate
  • DIDA diisodecyl adipate Esters
  • DOZ diazodiacid (2-ethylhexyl)
  • DOS diethylhexyl sebacate
  • DBS dibutyl sebacate
  • illustrative examples of phosphate esters that can be used in the present disclosure include, but are not limited to, tributyl phosphate (TBP), tris(2-ethylhexyl) phosphate (TOP), diphenyloctyl phosphate Ester (DPOP), triphenyl phosphate (TPP) and triisopropyl phenyl phosphate (IPPP).
  • TBP tributyl phosphate
  • TOP tris(2-ethylhexyl) phosphate
  • DPOP diphenyloctyl phosphate Ester
  • TPP triphenyl phosphate
  • IPPP triisopropyl phenyl phosphate
  • epoxides that can be used in the present disclosure include, but are not limited to, epoxy soybean oil (ESO), epoxidized linseed oil, epoxy fatty acid butyl ester (EBSt), octyl oleate Ester epoxide and di-2-ethylhexyl) 4,5-epoxytetrahydrophthalate (EPS).
  • ESO epoxy soybean oil
  • EBSt epoxy fatty acid butyl ester
  • EPS octyl oleate Ester epoxide and di-2-ethylhexyl) 4,5-epoxytetrahydrophthalate
  • polyethylene glycol (PEG) that can be used in the present disclosure has a relative molecular weight of at least about 4,000.
  • polyethylene glycol (PEG) that can be used in the present disclosure has a relative molecular weight of at least about 6,000.
  • polyethylene glycol (PEG) that can be used in the present disclosure has a relative molecular weight of at least about 8,000.
  • illustrative examples of polyethylene glycol (PEG) that can be used in the present disclosure include, but are not limited to: 4000, 6000, 8000, 4000, 6000, 8000, E 4000, E 6000 and E 8000.
  • illustrative examples of bulking agents that can be used in the present disclosure include, but are not limited to, crospovidone, sodium carboxymethyl starch, pregelatinized starch, croscarmellose sodium, croscarmellose Calcium dicarboxymethyl cellulose and low-substituted hydroxypropyl cellulose.
  • the gastro-retentive tablet of the present disclosure includes a first coating layer outside the sustained-release layer.
  • the first coating layer of the present disclosure comprises a water-soluble polymer.
  • illustrative examples of water-soluble polymers that can be used in the first coating layer of the present disclosure include, but are not limited to, a mixture comprising polyethylene glycol and polyvinyl alcohol, sodium alginate, hypromellose Polyvinyl alcohol, polyvinyl alcohol and polyvinyl alcohol-polyethylene glycol graft polymer.
  • illustrative examples of water-soluble polymers that can be used in the first coating layer of the present disclosure include, but are not limited to, a mixture comprising polyethylene glycol and polyvinyl alcohol and polyvinyl alcohol-polyethylene glycol Graft polymer.
  • illustrative examples of mixtures comprising polyethylene glycol and polyvinyl alcohol that can be used in the present disclosure include, but are not limited to II.
  • polyvinyl alcohol-polyethylene glycol graft polymers that can be used in the present disclosure include, but are not limited to IR.
  • the first coating layer of the present disclosure contains a second active pharmaceutical ingredient.
  • second active pharmaceutical ingredients include, but are not limited to, dipeptidyl peptidase-4 (dipeptidyl peptidase-4, DPP-4) inhibitors, sodium-glucose co- Transporter 2 (sodium/glucose cotranspoter 2, SGLT-2) inhibitors, sulfonylureas, non-sulfonylurea, ⁇ -glucosidase inhibitor, and insulin Sensitizer (insulin sensitizer).
  • dipeptidyl peptidase-4 dipeptidyl peptidase-4, DPP-4
  • sodium-glucose co- Transporter 2 sodium/glucose cotranspoter 2, SGLT-2
  • sulfonylureas sulfonylureas
  • non-sulfonylurea non-sulfonylurea
  • ⁇ -glucosidase inhibitor insulin Sensitizer
  • illustrative examples of sodium/glucose cotranspoter 2 (SGLT-2) inhibitors that can be used in the present disclosure include, but are not limited to, tofogliflozin, en Empagliflozin, ipragliflozin L-proline, luseogliflozin, dapagliflozin propanediol, canagliflozin, egliflozin Ertugliflozin (ertugliflozin).
  • illustrative examples of sulfonylureas capable of the present disclosure include but are not limited to: glipizide, gliclazide, glibenclamide ), glibornuride (glibornuride), glimepiride (glimepiride) and gliquidone (gliquidone).
  • non-sulfonylureas that can be used in the present disclosure include, but are not limited to, repaglinide and nateglinide.
  • alpha-glycosidase inhibitors include, but are not limited to, acarbose and voglibose.
  • insulin sensitizers that can be used in the present disclosure include, but are not limited to, rosiglitazone and pioglitazone.
  • the tablet core of the present disclosure includes a third active pharmaceutical ingredient.
  • exemplary examples of the third active pharmaceutical ingredient include, but are not limited to, dipeptidyl peptidase-4 (dipeptidyl peptidase-4, DPP-4) inhibitors, sodium-glucose co- Transporter 2 (sodium/glucose cotranspoter 2, SGLT-2) inhibitors, sulfonylureas, non-sulfonylurea, ⁇ -glucosidase inhibitor, and insulin Sensitizer (insulin sensitizer).
  • dipeptidyl peptidase-4 dipeptidyl peptidase-4, DPP-4
  • sodium-glucose co- Transporter 2 sodium/glucose cotranspoter 2, SGLT-2
  • sulfonylureas sulfonylureas
  • non-sulfonylurea non-sulfonylurea
  • ⁇ -glucosidase inhibitor insulin Sensitizer
  • illustrative examples of sodium/glucose cotranspoter 2 (SGLT-2) inhibitors that can be used in the present disclosure include, but are not limited to, tofogliflozin, en Empagliflozin, ipragliflozin L-proline, luseogliflozin, dapagliflozin propanediol, canagliflozin, egliflozin Ertugliflozin (ertugliflozin).
  • illustrative examples of sulfonylureas capable of the present disclosure include but are not limited to: glipizide, gliclazide, glibenclamide ), glibornuride (glibornuride), glimepiride (glimepiride) and gliquidone (gliquidone).
  • non-sulfonylureas that can be used in the present disclosure include, but are not limited to, repaglinide and nateglinide.
  • alpha-glycosidase inhibitors include, but are not limited to, acarbose and voglibose.
  • insulin sensitizers that can be used in the present disclosure include, but are not limited to, rosiglitazone and pioglitazone.
  • the gastro-retentive tablet of the present disclosure includes a second coating layer outside the sustained-release layer.
  • the second coating layer of the present disclosure comprises a water-soluble polymer.
  • illustrative examples of water-soluble polymers that can be used in the second coating layer of the present disclosure include, but are not limited to, sodium alginate, hypromellose, polyvinyl alcohol, polyvinyl alcohol-poly Ethylene glycol graft polymers and mixtures containing polyethylene glycol and polyvinyl alcohol.
  • illustrative examples of water-soluble polymers that can be used in the second coating layer of the present disclosure include, but are not limited to, sodium alginate, hypromellose, polyvinyl alcohol, polyvinyl alcohol-poly Ethylene glycol graft polymers and mixtures containing polyethylene glycol and polyvinyl alcohol.
  • illustrative examples of mixtures comprising polyethylene glycol and polyvinyl alcohol that can be used in the present disclosure include, but are not limited to II.
  • polyvinyl alcohol-polyethylene glycol graft polymers that can be used in the present disclosure include, but are not limited to IR.
  • the gastro-retentive tablet of the present disclosure includes a barrier layer between the tablet core and the sustained-release layer, a first coating layer outside the sustained-release layer, and a second coating layer outside the first coating layer. Clothing layer.
  • the core of the gastro-retentive tablet of the present disclosure further includes a filler.
  • illustrative examples of fillers that can be used in the present disclosure include, but are not limited to, lactose, glucose, sucrose, xylitol, mannitol, sorbitol, maltodextrin, powdered sugar, dextrins, Microcrystalline cellulose, inorganic salts, mannitol and starch.
  • the core of the gastric retentive tablet of the present disclosure further comprises a glidant.
  • illustrative examples of glidants that can be used in the tablet cores of the present disclosure include, but are not limited to, colloidal silica, micronized silica gel, polyethylene glycol, magnesium stearate, stearic acid , Talcum powder and starch.
  • the core of the gastro-retentive tablet of the present disclosure further includes a binder.
  • the core of the gastro-retentive tablet of the present disclosure further includes a lubricant.
  • illustrative examples of lubricants that can be used in the tablet cores of the present disclosure include, but are not limited to, glyceryl behenate, fatty acids and their metal soaps, esters, hydrogenated vegetable oils, polyethylene glycols Class and magnesium lauryl sulfate.
  • illustrative examples of fatty acids and metal soaps that can be used in the present disclosure include, but are not limited to, magnesium stearate, stearic acid, zinc stearate, calcium stearate, lead stearate , Barium stearate and hard sodium fumarate.
  • the core of the gastric retentive tablet of the present disclosure is a single layer.
  • the core of the gastric retentive tablet of the present disclosure is a double layer.
  • the core of the gastric retentive tablet of the present disclosure is three layers.
  • the core of the gastric retentive tablet of the present disclosure is a single compartment.
  • the core of the gastric retentive tablet of the present disclosure is a dual-compartment.
  • the core of the gastric retentive tablet of the present disclosure is three compartments.
  • the hardness of the core of the gastric retentive tablet of the present disclosure is about 5 to 15 kp.
  • the gastro-retentive tablet of the present disclosure can be floated within 10 minutes in an aqueous medium.
  • the gastric-retentive tablet of the present disclosure can be immediately bleached in an aqueous medium.
  • the short diameter of the gastroretentive tablet of the present disclosure is no greater than about 9 mm, and its thickness is no greater than the short diameter.
  • the gastroretentive tablets of the present disclosure have a tablet weight of no more than about 800 mg.
  • the short diameter of the gastro-retentive tablet of the present disclosure after swelling in an aqueous medium is not less than about 11 mm.
  • the sustained-release layer coating has good tension.
  • the present disclosure relates to a method of preparing a gastric retention tablet, which includes:
  • the tablet with the isolation layer is coated with a sustained-release layer to obtain the gastric retention tablet.
  • the method of the present disclosure further includes performing a first coating after coating the sustained-release layer to obtain the first coating layer.
  • the first coating layer of the present disclosure comprises a water-soluble polymer.
  • illustrative examples of water-soluble polymers that can be used in the first coating layer of the present disclosure include, but are not limited to, a mixture comprising polyethylene glycol and polyvinyl alcohol, sodium alginate, hypromellose Polyvinyl alcohol, polyvinyl alcohol and polyvinyl alcohol-polyethylene glycol graft polymer.
  • illustrative examples of water-soluble polymers that can be used in the first coating layer of the present disclosure include, but are not limited to, a mixture comprising polyethylene glycol and polyvinyl alcohol and polyvinyl alcohol-polyethylene glycol Graft polymer.
  • illustrative examples of mixtures comprising polyethylene glycol and polyvinyl alcohol that can be used in the present disclosure include, but are not limited to II.
  • polyvinyl alcohol-polyethylene glycol graft polymers that can be used in the present disclosure include, but are not limited to IR.
  • the first coating layer of the present disclosure contains a second active pharmaceutical ingredient.
  • exemplary examples of the second active pharmaceutical ingredient include, but are not limited to, dipeptidyl peptidase-4 (dipeptidyl peptidase-4, DPP-4) inhibitors, sodium-glucose cotransport Body 2 (sodium/glucose cotransporter 2, SGLT-2) inhibitors, sulfonylureas, non-sulfonylureas, ⁇ -glycosidase inhibitors, insulin boosters Sensitizer (insulin sensitizer).
  • illustrative examples of sodium/glucose cotranspoter 2 (SGLT-2) inhibitors that can be used in the present disclosure include, but are not limited to, tofogliflozin, en Empagliflozin, ipragliflozin L-proline, luseogliflozin, dapagliflozin propanediol, canagliflozin, egliflozin Ertugliflozin (ertugliflozin).
  • illustrative examples of sulfonylureas capable of the present disclosure include, but are not limited to: glipizide, gliclazide, glibenclamide ), glibornuride (glibornuride), glimepiride (glimepiride) and gliquidone (gliquidone).
  • non-sulfonylureas that can be used in the present disclosure include, but are not limited to, repaglinide and nateglinide.
  • alpha-glycosidase inhibitors include, but are not limited to, acarbose and voglibose.
  • insulin sensitizers that can be used in the present disclosure include, but are not limited to, rosiglitazone and pioglitazone.
  • the tablet core of the present disclosure includes a third active pharmaceutical ingredient.
  • exemplary examples of the third active pharmaceutical ingredient include, but are not limited to, dipeptidyl peptidase-4 (dipeptidyl peptidase-4, DPP-4) inhibitors, sodium-glucose co- Transporter 2 (sodium/glucose cotranspoter 2, SGLT-2) inhibitors, sulfonylureas, non-sulfonylurea, ⁇ -glucosidase inhibitor, and insulin Sensitizer (insulin sensitizer).
  • dipeptidyl peptidase-4 dipeptidyl peptidase-4, DPP-4
  • sodium-glucose co- Transporter 2 sodium/glucose cotranspoter 2, SGLT-2
  • sulfonylureas sulfonylureas
  • non-sulfonylurea non-sulfonylurea
  • ⁇ -glucosidase inhibitor insulin Sensitizer
  • illustrative examples of sodium/glucose cotranspoter 2 (SGLT-2) inhibitors that can be used in the present disclosure include, but are not limited to, tofogliflozin, en Empagliflozin, ipragliflozin L-proline, luseogliflozin, dapagliflozin propanediol, canagliflozin, egliflozin Ertugliflozin (ertugliflozin).
  • illustrative examples of sulfonylureas capable of the present disclosure include, but are not limited to: glipizide, gliclazide, glibenclamide ), glibornuride (glibornuride), glimepiride (glimepiride) and gliquidone (gliquidone).
  • non-sulfonylureas that can be used in the present disclosure include, but are not limited to, repaglinide and nateglinide.
  • alpha-glycosidase inhibitors include, but are not limited to, acarbose and voglibose.
  • insulin sensitizers that can be used in the present disclosure include, but are not limited to, rosiglitazone and pioglitazone.
  • the gastro-retentive tablet of the present disclosure includes a second coating layer outside the sustained-release layer.
  • the second coating layer of the present disclosure contains a water-soluble polymer.
  • illustrative examples of water-soluble polymers that can be used in the second coating layer of the present disclosure include, but are not limited to, sodium alginate, hypromellose, polyvinyl alcohol, polyvinyl alcohol-poly Ethylene glycol graft polymers and mixtures containing polyethylene glycol and polyvinyl alcohol.
  • illustrative examples of water-soluble polymers that can be used in the second coating layer of the present disclosure include, but are not limited to, sodium alginate, hypromellose, polyvinyl alcohol, polyvinyl alcohol-poly Ethylene glycol graft polymers and mixtures containing polyethylene glycol and polyvinyl alcohol.
  • illustrative examples of mixtures comprising polyethylene glycol and polyvinyl alcohol that can be used in the present disclosure include, but are not limited to II.
  • polyvinyl alcohol-polyethylene glycol graft polymers that can be used in the present disclosure include, but are not limited to IR.
  • illustrative examples of bulking agents that can be used in the present disclosure include, but are not limited to, sodium starch glycolate, pregelatinized starch, croscarmellose sodium, croscarmellose calcium And low-substituted hydroxypropyl cellulose.
  • the sustained-release layer in the gastroretentive tablet of the present disclosure contains a mixture comprising polyvinyl acetate and povidone.
  • the sustained-release layer in the gastric retention tablet of the present disclosure contains a polymer of ethyl acrylate and methyl methacrylate monomers.
  • the sustained-release layer in the gastric retention tablet of the present disclosure contains a polymer comprising a mixture of polyvinyl acetate and povidone and monomers of ethyl acrylate and methyl methacrylate.
  • illustrative examples of mixtures comprising polyvinyl acetate and povidone that can be used in the present disclosure include, but are not limited to SR.
  • illustrative examples of polymers that can be used in the ethyl acrylate and methyl methacrylate monomers of the present disclosure include, but are not limited to NE 30D.
  • the weight ratio of the sustained-release layer of the gastroretentive tablet of the present disclosure comprising a mixture of polyvinyl acetate and povidone to a polymer of ethyl acrylate and methyl methacrylate monomers is about 1:20 to 20:1.
  • the method of preparing particles comprising metformin or a pharmaceutically acceptable salt thereof includes, but is not limited to, the use of fluidized bed granulation.
  • illustrative examples of methods that can be used in the present disclosure to prepare particles comprising metformin or a pharmaceutically acceptable salt thereof include, but are not limited to, wet granulation and dry granulation.
  • examples of wet granulation that can be used in the present disclosure include, but are not limited to, fluidized bed granulation, wet granulation machine-made granulation, and manual wet granulation.
  • the present disclosure relates to a gastric retention tablet, which is prepared by a method including the following steps to prepare a tablet core containing a first active pharmaceutical ingredient and a swelling agent;
  • the tablet with the isolation layer is coated with a sustained-release layer to obtain the gastric retention tablet.
  • the method of the present disclosure further includes performing a first coating after coating the sustained-release layer to obtain a tablet having the first coating layer.
  • the first coating layer of the present disclosure comprises a water-soluble polymer.
  • the first coating layer of the present disclosure contains a second active pharmaceutical ingredient.
  • the gastro-retentive tablet of the present disclosure includes a second coating after coating with a sustained-release layer, thereby obtaining a tablet with a second coating layer.
  • the second coating layer of the present disclosure comprises a water-soluble polymer.
  • the core of the gastric retentive tablet of the present disclosure is a single layer.
  • the core of the gastric retentive tablet of the present disclosure is a double layer.
  • the core of the gastric retentive tablet of the present disclosure is three layers.
  • the core of the gastric retentive tablet of the present disclosure is a single compartment.
  • the core of the gastric retentive tablet of the present disclosure is a dual-compartment.
  • the core of the gastric retentive tablet of the present disclosure is three compartments.
  • the hardness of the core of the gastric retentive tablet of the present disclosure is about 5 to 15 kp.
  • the gastro-retentive tablet of the present disclosure can be floated within 10 minutes in an aqueous medium.
  • the gastric-retentive tablet of the present disclosure can be immediately bleached in an aqueous medium.
  • the short diameter of the gastroretentive tablet of the present disclosure is no greater than about 9 mm, and its thickness is no greater than the short diameter.
  • the gastroretentive tablets of the present disclosure have a tablet weight of no more than about 800 mg.
  • the short diameter of the gastro-retentive tablet of the present disclosure after swelling in an aqueous medium is not less than about 11 mm.
  • the sustained-release layer coating has good tension.
  • the present disclosure relates to a method for improving the compliance of an individual, which comprises administering a gastric-retentive tablet to the individual in need of the method, wherein the gastric-retentive tablet comprises a tablet core, a sustained-release layer, and a tablet core. And the isolation layer between the sustained-release layer, wherein the tablet core contains the first active pharmaceutical ingredient and a swelling agent.
  • the gastro-retentive tablet of the present disclosure includes a first coating layer outside the sustained-release layer.
  • the first coating layer of the present disclosure comprises a water-soluble polymer.
  • the first coating layer of the present disclosure contains a second active pharmaceutical ingredient.
  • the gastro-retentive tablet of the present disclosure includes a second coating layer outside the sustained-release layer.
  • the second coating layer of the present disclosure comprises a water-soluble polymer.
  • illustrative examples of individuals that can be used in the present disclosure include, but are not limited to, mammals.
  • illustrative examples of mammals that can be used in the present disclosure include, but are not limited to, dogs, cats, cows, sheep, horses, and humans.
  • the mammal is a human.
  • the prepared metformin hydrochloride granules and the prescription amount of colloidal silica were mixed for 40 revolutions, the prescription amount of crospovidone was added, and the mixture was mixed for 100 minutes, and finally the prescription amount of glyceryl behenate was added, and the tablets were lubricated for 50 revolutions.
  • the prescription is shown in Table 3.
  • the isolation layer auxiliary materials weigh the isolation layer auxiliary materials to disperse or dissolve in pure water, stir until uniform as the isolation layer coating liquid.
  • the temperature of the material is controlled to be 30 to 45°C, and the coating weight increases by 1 to 5%.
  • the temperature of the material is controlled to be 30 to 45°C, and the coating weight increases by 5 to 15%.
  • the prepared metformin hydrochloride granules and the prescription amount of colloidal silica were mixed for 40 revolutions, the prescription amount of crospovidone was added, and the mixture was mixed for 100 minutes, and finally the prescription amount of glyceryl behenate was added, and the tablets were lubricated for 50 revolutions.
  • the prescription is shown in Table 3.
  • the isolation layer auxiliary materials weigh the isolation layer auxiliary materials to disperse or dissolve in pure water, stir until uniform as the isolation layer coating liquid.
  • the temperature of the material is controlled to be 30 to 45°C, and the coating weight increases by 1 to 5%.
  • the temperature of the material is controlled to be 30 to 45°C, and the coating weight increases by 5 to 15%.
  • the prepared metformin hydrochloride granules and the prescription amount of colloidal silica were mixed for 40 revolutions, the prescription amount of crospovidone was added, and the mixture was mixed for 100 minutes, and finally the prescription amount of glyceryl behenate was added, and the tablets were lubricated for 50 revolutions.
  • the prescription is shown in Table 3.
  • the isolation layer auxiliary materials weigh the isolation layer auxiliary materials to disperse or dissolve in pure water, stir until uniform as the isolation layer coating liquid.
  • the temperature of the material is controlled to be 30 to 45°C, and the coating weight increases by 1 to 5%.
  • the temperature of the material is controlled to be 30 to 45°C, and the weight of the coating is increased by 5 to 15%.
  • the prepared metformin hydrochloride granules and the prescription amount of colloidal silica were mixed for 40 revolutions, the prescription amount of crospovidone was added, and the mixture was mixed for 100 minutes, and finally the prescription amount of glyceryl behenate was added, and the tablets were lubricated for 50 revolutions.
  • the prescription is shown in Table 3.
  • the isolation layer auxiliary materials weigh the isolation layer auxiliary materials to disperse or dissolve in pure water, stir until uniform as the isolation layer coating liquid.
  • the temperature of the material is controlled to be 30 to 45°C, and the weight of the coating is 1 to 5%.
  • the temperature of the material is controlled to be 30 to 45°C, and the coating weight increases by 5 to 15%.
  • metformin hydrochloride sustained-release tablets prepared in Examples 1 to 4.
  • Example 1 sample set 3 parallel samples
  • Example 2 samples are set up in 3 parallel samples
  • the sample of Example 4 set 3 parallel samples.
  • the release test was measured by Sotax dissolution apparatus and Shimadzu UV spectrophotometer.
  • Dissolution medium pH 1.2 hydrochloric acid solution preparation method Measure 53.55 mL of concentrated hydrochloric acid, dilute to 7000 mL with water, and mix well to obtain a pH 1.2 hydrochloric acid solution.
  • Time/h Piece 1 Piece 2 Piece 3 average value RSD(%) 0 0.00 0.00 0.00 0.00 0.00 1 8.50 6.99 7.38 7.62 10.24 2 20.87 18.95 19.11 19.64 5.41 4 41.09 37.45 37.01 38.52 5.81 6 60.63 54.15 53.04 55.94 7.33 8 74.08 69.11 67.68 70.29 4.78 10 83.99 79.78 78.66 80.81 3.47 12 89.30 86.68 85.51 87.16 2.22 14 91.98 90.82 90.11 90.97 1.03 16 93.73 93.28 92.48 93.16 0.68
  • relational terms such as first and second are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any difference between these entities or operations.
  • kind of actual relationship or sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一种胃滞留片，其包含片芯、缓释层以及在所述片芯和所述缓释层之间的隔离层，其中所述片芯含有第一活性药物成分和膨胀剂，该制剂能够改善个体的顺应性。

Description

胃滞留片
本公开要求于2019年12月31日向中华人民共和国国家知识产权局提交的申请号为201911410594.2、发明名称为“胃滞留片”，申请号为201911419340.7、发明名称为“胃滞留片”，以及申请号为201911419357.2、发明名称为“胃滞留片”的发明专利申请的全部权益，并通过引用的方法将其全部内容整体并入本公开中。
领域
本公开大体上涉及医药领域。更具体地，本申请涉及药物制剂领域。
背景
胃内滞留释药系统是利用胃肠道局部pH值、胃肠道酶、制剂在胃肠道的转运机制等生理学特性，通过改变制剂的物理化学性质以延长药物在胃内滞留时间的给药系统。
概述
一方面，本公开涉及胃滞留片，其包含片芯、缓释层以及在所述片芯和所述缓释层之间的隔离层，其中所述片芯含有第一活性药物成分和膨胀剂。
另一方面，本公开涉及制备胃滞留片的方法，其包括：制备含有第一活性药物成分和膨胀剂的片芯；对所述片芯进行隔离层包衣，从而得到具有隔离层的片，以及对所述具有隔离层的片进行缓释层包衣，从而得到所述胃滞留片。
再一方面，本公开涉及胃滞留片，其由包括如下步骤的方法制备得到，制备含有第一活性药物成分和膨胀剂的片芯；对所述片芯进行隔离层包衣，从而得到具有隔离层的片，以及对所述具有隔离层的片进行缓释层包衣，从而得到所述胃滞留片。
又一方面，本公开涉及改善个体的顺应性的方法，其包括向需要所述方法的所述个体给予胃滞留片，其中所述胃滞留片包含片芯、缓 释层以及在所述片芯和所述缓释层之间的隔离层，其中所述片芯含有第一活性药物成分和膨胀剂。
附图简要说明
图1示出了本公开实施例1的盐酸二甲双胍缓释片膨胀后的电镜图(300倍放大)。
图2示出了本公开实施例1的盐酸二甲双胍缓释片膨胀后的电镜图(500倍放大)。
图3示出了本公开实施例2的盐酸二甲双胍缓释片膨胀后的电镜图(300倍放大)。
图4示出了本公开实施例2的盐酸二甲双胍缓释片膨胀后的电镜图(500倍放大)。
图5示出了本公开实施例3的盐酸二甲双胍缓释片膨胀后的电镜图(300倍放大)。
图6示出了本公开实施例3的盐酸二甲双胍缓释片膨胀后的电镜图(500倍放大)。
图7示出了本公开实施例4的盐酸二甲双胍缓释片膨胀后的电镜图(300倍放大)。
图8示出了本公开实施例4的盐酸二甲双胍缓释片膨胀后的电镜图(500倍放大)。
图9示出了本公开实施例1至4的盐酸二甲双胍缓释片的累积释放曲线。
详述
在以下的说明中，包括某些具体的细节以对各个公开的实施方案提供全面的理解。然而，相关领域的技术人员会认识到，不采用一个或多个这些具体的细节，而采用其它方法、部件、材料等的情况下仍实现实施方案。
除非本申请中另有要求，在整个说明书和所附的权利要求书中，词语“包括”、“包含”、“含有”和“具有”应解释为开放式的、含括式的意 义，即“包括但不限于”。
在整个说明书中提到的“一实施方案”、“实施方案”、“在另一实施方案中”或“在某些实施方案中”意指在至少一实施方案中包括与该实施方案所述的相关的具体参考要素、结构或特征。因此，在整个说明书中不同位置出现的短语“在一实施方案中”或“在实施方案中”或“在另一实施方案中”或“在某些实施方案中”不必全部指同一实施方案。此外，具体要素、结构或特征可以任何适当的方式在一个或多个实施方案中结合。
定义
在本公开中，术语“药物可接受的盐”包括“可以接受的酸加合盐”和“可以接受的碱加合盐”。
在本公开中，术语“可以接受的酸加合盐”系指保持游离碱的生物学有效性和性质的那些盐，所述酸加合盐是在生物学或其它方面合适的并且是使用无机酸或有机酸来形成的，所述无机酸例如但不限于盐酸、氢溴酸、硫酸、硝酸、磷酸等，所述有机酸例如但不限于乙酸、2,2-二氯乙酸、己二酸、褐藻酸、抗坏血酸、天冬氨酸、苯磺酸、苯羧酸、4-乙酰胺基苯羧酸、樟脑酸、樟脑-10-磺酸、癸酸、己酸、辛酸、碳酸、肉桂酸、柠檬酸、环己烷基氨基磺酸、十二烷基硫酸、乙烷-1,2-二磺酸、乙烷磺酸、2-羟基乙烷磺酸、甲酸、富马酸、粘酸、龙胆酸、葡庚糖酸、葡糖酸、葡糖醛酸、谷氨酸、戊二酸、2-氧代-戊二酸、甘油磷酸、乙醇酸、马尿酸、异丁酸、乳酸、乳糖醛酸、月桂酸、马来酸、苹果酸、丙二酸、扁桃酸、甲烷磺酸、黏酸、萘-1,5-二磺酸、萘-2-磺酸、1-羟基-2-萘甲酸、烟酸、油酸、乳清酸、草酸、棕榈酸、双羟萘酸、丙酸、焦谷氨酸、丙酮酸、水杨酸、4-氨基水杨酸、癸二酸、硬脂酸、丁二酸、酒石酸、硫氰酸、对甲苯磺酸、三氟乙酸、十一碳烯酸等。
在本公开中，术语“可以接受的碱加合盐”系指保持游离酸的生物学有效性和性质的那些盐，所述碱加合盐是在生物学或其它方面合适的。向游离酸中加入无机碱或有机碱来制备这些盐。由无机碱衍生的 盐包括但不限于钠、钾、锂、铵、钙、镁、铁、锌、铜、锰、铝盐等。在某些实施方案中，无机盐为铵、钠、钾、钙及镁盐。由有机碱衍生的盐包括但不限于伯、仲和叔胺的盐、包括天然存在的取代的胺在内的取代的胺、环胺和碱性离子交换树脂的盐，例如氨、异丙胺、三甲胺、二乙胺、三乙胺、三丙胺、二乙醇胺、乙醇胺、2-二甲氨基乙醇、2-二乙氨基乙醇、二环己胺、赖氨酸、精氨酸、组氨酸、咖啡因、普鲁卡因、海巴明、胆碱、甜菜碱、苄胺、苯乙二胺、乙二胺、葡萄糖胺、甲基葡糖胺、可可碱、三乙醇胺、氨基丁三醇、嘌呤、哌嗪、哌啶、N-乙基哌啶、聚胺树脂等。在某些实施方案中，有机碱是异丙胺、二乙胺、乙醇胺、三甲胺、二环己胺、胆碱和咖啡因。
在本公开中，术语“活性药物成分(activepharmaceutical ingredient)”系指一种化学实体，它可以有效地治疗目标紊乱、疾病或病症。
在本公开中，术语“隔离层”系指设置在含有活性药物成分的片芯和缓释层之间的起到防止活性药物成分与缓释层相互作用(即隔离)的层。
在本公开中，术语“膨胀剂”系指置于含水环境中可吸收水分并发生体积膨胀的辅料。
在本公开中，术语“致孔剂”系指分散在缓释衣膜的高分子材料中的水溶性辅料，当片剂接触水性液体后溶解，使缓释衣膜具有微孔和通透性。
在本公开中，术语“粘合剂”系指使物料贴结，方便制粒的辅料。
在本公开中，术语“助流剂”系指降低颗粒之间的摩擦力，从而改善粉体流动性的辅料。
在本公开中，术语“润滑剂”系指降低颗粒之间的摩擦力，从而改善粉体流动性的辅料。
在本公开中，术语“增塑剂”系指在结构上具有极性或部分具有极性的辅料，其具有高沸点、难挥发与聚合物有良好混溶性等特点，增塑剂分布在大分子链之间，能降低分子间作用力，使聚合物粘度降低，柔韧性增强。
在本公开中，术语“遮光剂”系指可以吸收、散射或反射光线的物质。
在本公开中，术语“消泡剂”系指能够降低水、溶液、悬浮液等的表面张力，防止泡沫形成，或使原有泡沫减少或消灭的物质。
在本公开中，术语“表面活性剂”系指能使液体表面张力发生明显降低的物质。
在本公开中，术语“水性介质”系指水或以水为溶媒的液体体系。
在本公开中，术语“短径”系指胃内滞留制剂最短的直径。
在本公开中，术语“顺应性”系指个体按医生规定进行治疗，其行为与医嘱一致；反之则称为非顺应性。
具体实施方式
一方面，本公开涉及胃滞留片，其包含片芯、缓释层以及在所述片芯和所述缓释层之间的隔离层，其中所述片芯含有第一活性药物成分和膨胀剂。
在某些实施方案，本公开的胃滞留片中的缓释层含有包含聚醋酸乙烯酯和聚维酮的混合物。
在某些实施方案，本公开的胃滞留片中的缓释层含有丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物。
在某些实施方案，本公开的胃滞留片中的缓释层含有包含聚醋酸乙烯酯和聚维酮的混合物与丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物。
在某些实施方案中，能够用于本公开的包含聚醋酸乙烯酯和聚维酮的混合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000001
SR。
在某些实施方案中，能够用于本公开的丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000002
NE30D。
在某些实施方案中，本公开的胃滞留片中的缓释层中包含聚醋酸乙烯酯和聚维酮的混合物与丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物的重量比约为1:20至20:1。
在某些实施方案中，能够用于本公开的第一活性药物成分的示例 性实例选自左旋多巴、盐酸甲氨二氮卓、地西泮、呋喃苯胺酸、卡托普利、琥珀酸美托洛尔、马来酸罗格列酮、维拉帕米、阿替洛尔、氯沙坦、己酮可可碱、尼莫地平、桂利嗪、地尔硫卓、吡咯他尼、硝酸异山梨酯、索他洛尔、普萘洛尔、盐酸塞利洛尔、消胆胺、硝苯地平、双嘧达莫、葡萄糖酸奎尼丁、洛伐他汀、盐酸曲美他嗪、尼卡地平、单硝酸异山梨酯、甲硝唑、克拉霉素、呋喃妥因、氧氟沙星、头孢氨苄、齐多夫定、环丙沙星、灰黄霉素、氨苄西林、酮洛芬、布洛芬、吡罗昔康、氟比洛芬、吲哚美辛、双氯芬酸钠、马来酸氯苯那敏、茶碱、氟尿嘧啶、核黄素-5'-磷酸钠、米索前列醇、熊去氧胆酸、牛磺熊去氧胆酸、胃酶抑素、曲尼司特、特非那定、奥利司他、阿苯达唑、氢化泼尼松、氯雷他定、卡比多巴与左旋多巴、左旋多巴与苄丝肼、普瑞巴林、盐酸二甲双胍、阿莫西林、阿昔洛韦和加巴喷丁。
在某些实施方案中，能够用于本公开的第一活性药物成分的示例性实例包括但不限于卡比多巴与左旋多巴、左旋多巴与苄丝肼、普瑞巴林、盐酸二甲双胍、阿莫西林、阿昔洛韦和加巴喷丁。
在某些实施方案中，本公开的隔离层包含水溶性聚合物。
在某些实施方案中，能够用于本公开的隔离层的水溶性聚合物的示例性实例包括但不限于海藻酸钠、羟丙甲纤维素、聚乙烯醇、聚乙烯醇-聚乙二醇接枝聚合物以及包含聚乙二醇和聚乙烯醇的混合物。
在某些实施方案中，能够用于本公开的隔离层的水溶性聚合物的示例性实例包括但不限于聚乙烯醇-聚乙二醇接枝聚合物。
在某些实施方案中，能够用于本公开的聚乙烯醇-聚乙二醇接枝聚合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000003
IR。
在某些实施方案中，能够用于本公开的包含聚乙二醇和聚乙烯醇的混合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000004
II。
在某些实施方案中，本公开的缓释层包含致孔剂。
在某些实施方案中，能够用于本公开的致孔剂的示例性实例包括但不限于水溶性聚合物。
在某些实施方案中，能够用于本公开的用作致孔剂的水溶性聚合物的示例性实例包括但不限于海藻酸钠、羟丙甲纤维素、羟丙基纤维 素、聚维酮、聚乙二醇和聚乙烯醇-聚乙二醇接枝聚合物。
在某些实施方案中，能够用于本公开的用作致孔剂的水溶性聚合物的示例性实例包括但不限于羟丙甲纤维素、羟丙基纤维素、聚维酮、聚乙二醇和聚乙烯醇。
在某些实施方案中，能够用于本公开的作为致孔剂的水溶性聚合物的示例性实例包括但不限于其2％溶液在约20℃下粘度在3mpa·s以上至50mpa·s以下的羟丙甲纤维素、其2％溶液在约20℃下粘度在75mpa·s以上至3,000mpa·s以下的羟丙基纤维素、聚维酮K12、聚维酮K17、聚维酮K25、聚维酮K30、聚维酮K90、分子量在1,000以上至20,000以下的聚乙二醇和聚乙烯醇-聚乙二醇接枝聚合物。
在某些实施方案中，能够用于本公开的作为致孔剂的水溶性聚合物的示例性实例包括但不限于Methocel TM E3、Methocel TM E5、Methocel TM E6、Benecel TM E3、Benecel TM E5、Benecel TM E6和
Figure PCTCN2020142069-appb-000005
IR。
在某些实施方案中，本公开的缓释层包含助流剂。
在某些实施方案中，能够用于本公开的片芯中的助流剂的示例性实例包括但不限于胶态二氧化硅、微粉硅胶、聚乙二醇、硬脂酸镁、硬脂酸、滑石粉和淀粉。
在某些实施方案中，本公开的缓释层包含遮光剂。
在某些实施方案中，能够用于本公开的遮光剂的示例性实例包括但不限于二氧化钛和滑石粉。
在某些实施方案中，本公开的缓释层包含消泡剂。
在某些实施方案中，能够用于本公开的消泡剂的示例性实例包括但不限于二甲基硅油以及二甲基硅油和二氧化硅的混合物。
在某些实施方案中，本公开的缓释层包含表面活性剂。
在某些实施方案中，能够用于本公开的表面活性剂的示例性实例包括但不限于阿拉伯胶、黄原胶、明胶、单硬脂酸丙二醇酯、单硬脂酸甘油酯、二硬脂酸乙烯酯、单甘油酸二甘油酯、十二烷基硫酸钠、Span 20、Span 40、Span 60、Span 65、Span 80、Span 83、Span 85、油酸钾、油酸钠、三乙醇胺油酸酯、卵磷脂、蔗糖酯、泊洛沙姆188、 Atlas G-263、吐温20、吐温21、吐温40、吐温60、吐温61、吐温65、吐温80、吐温81、吐温85、Myrj 45、Myrj 49、Myrj 51、Myrj 52、聚氧乙烯400单月桂酸酯、聚氧乙烯400单硬脂酸酯、聚氧乙烯400单油酸酯、Brij 35、Brij 30、鲸蜡甲基萘酚、聚氧乙烯氢化蓖麻油、聚氧乙烯烷基酚和聚氧乙烯壬基酚醚。
在某些实施方案中，本公开的缓释层包含增塑剂。
在某些实施方案中，能够用于本公开的增塑剂的示例性实例包括但不限于邻苯二甲酸酯、脂族二元酸酯、磷酸酯、环氧化物、脂肪酸酯和聚乙二醇。
在某些实施方案中，能够用于本公开的邻苯二甲酸酯的示例性实例包括但不限于邻苯二甲酸二甲酯(DMP)、邻苯二甲酸二乙酯(DEP)、邻苯二甲酸二丁酯(DBP)、邻苯二甲酸二辛酯(DOP)和邻苯二甲酸辛酯(DnOP)。
在某些实施方案中，能够用于本公开的脂族二元酸酯的示例性实例包括但不限于己二酸双(2-乙基己基)酯(DOA)、己二酸二异癸基酯(DIDA)、重氮二酸(2-乙基己酯)(DOZ)、癸二酸二乙基己酯(DOS)和癸二酸二丁酯(DBS)。
在某些实施方案中，能够用于本公开的磷酸酯的示例性实例包括但不限于磷酸三丁酯(TBP)、磷酸三(2-乙基己基)酯(TOP)、磷酸二苯辛基酯(DPOP)、三苯基磷酸酯(TPP)和三异丙基苯基磷酸酯(IPPP)。
在某些实施方案中，能够用于本公开的环氧化物的示例性实例包括但不限于环氧大豆油(ESO)、环氧化亚麻籽油、环氧脂肪酸丁酯(EBSt)、油酸辛酯环氧化物和二-2-乙基己基)4,5-环氧四氢邻苯二甲酸酯(EPS)。
在某些实施方案中，能够用于本公开的聚乙二醇(PEG)具有至少约4,000的相对分子量。
在某些实施方案中，能够用于本公开的聚乙二醇(PEG)具有至少约6,000的相对分子量。
在某些实施方案中，能够用于本公开的聚乙二醇(PEG)具有至少约8,000的相对分子量。
在某些实施方案中，能够用于本公开中的聚乙二醇(PEG)的示例性实例包括但不限于：
Figure PCTCN2020142069-appb-000006
4000、
Figure PCTCN2020142069-appb-000007
6000、
Figure PCTCN2020142069-appb-000008
8000、
Figure PCTCN2020142069-appb-000009
4000、
Figure PCTCN2020142069-appb-000010
6000、
Figure PCTCN2020142069-appb-000011
8000、
Figure PCTCN2020142069-appb-000012
E 4000、
Figure PCTCN2020142069-appb-000013
E 6000和
Figure PCTCN2020142069-appb-000014
E 8000。
在某些实施方案中，能够用于本公开的膨胀剂的示例性实例包括但不限于交联聚维酮、羧甲基淀粉钠、预胶化淀粉、交联羧甲基纤维素钠、交联羧甲基纤维素钙和低取代羟丙基纤维素。
在某些实施方案中，本公开的胃滞留片包含在缓释层外的第一包衣层。
在某些实施方案中，本公开的第一包衣层包含水溶性聚合物。
在某些实施方案中，能够用于本公开的第一包衣层的水溶性聚合物的示例性实例包括但不限于包含聚乙二醇和聚乙烯醇的混合物、海藻酸钠、羟丙甲纤维素、聚乙烯醇和聚乙烯醇-聚乙二醇接枝聚合物。
在某些实施方案中，能够用于本公开的第一包衣层的水溶性聚合物的示例性实例包括但不限于包含聚乙二醇和聚乙烯醇的混合物和聚乙烯醇-聚乙二醇接枝聚合物。
在某些实施方案中，能够用于本公开的包含聚乙二醇和聚乙烯醇的混合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000015
II。
在某些实施方案中，能够用于本公开的聚乙烯醇-聚乙二醇接枝聚合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000016
IR。
在某些实施方案中，本公开的第一包衣层含有第二活性药物成分。
在某些实施方案中，能够用于本公开的第二活性药物成分的示例性实例包括但不限于二肽基肽酶-4(dipeptidyle peptidase-4,DPP-4)抑制剂、钠-葡萄糖共转运体2(sodium/glucose cotranspoter 2,SGLT-2)抑制剂、磺酰脲类药物(sulfonylureas)、非磺酰脲类药物(non-sulfonylurea)、α-糖苷酶抑制剂(glucosidase inhibitor)和胰岛素增敏剂(insulin sensitizer)。
在某些实施方案中，能够用于本公开的二肽基肽酶-4(dipeptidyle peptidase-4,DPP-4)抑制剂的示例性实例包括但不限于西格列汀(sitagliptin)、维格列汀(vildagliptin)、沙格列汀(saxagliptin)、阿格列汀 (alogliptin)、利格列汀(linagliptin)、吉格列汀(gemigliptin)和替格列汀。
在某些实施方案中，能够用于本公开的钠-葡萄糖共转运体2(sodium/glucose cotranspoter 2,SGLT-2)抑制剂的示例性实例包括但不限于托格列净(tofogliflozin)、恩格列净(empagliflozin)、依格列净L-脯氨酸(ipragliflozin L-proline)、鲁格列净(luseogliflozin)、达格列净丙二醇(dapagliflozin propanediol)、卡格列净(canagliflozin)、埃格列净(ertugliflozin)。
在某些实施方案中，能够本公开的磺酰脲类药物(sulfonylureas)的示例性实例包括但不限于：格列吡嗪(glipizide)、格列齐特(gliclazide)、格列本脲(glibenclamide)、格列波脲(glibornuride)、格列美脲(glimepiride)和格列喹酮(gliquidone)。
在某些实施方案中，能够用于本公开的非磺酰脲类药物(non-sulfonylureas)的示例性实例包括但不限于瑞格列奈(repaglinide)和那格列奈(nateglinide)。
在某些实施方案中，能够用于本公开的α-糖苷酶抑制剂(glucosidase inhibitor)的示例性实例包括但不限于阿卡波糖(acarbose)和伏格列波糖(voglibose)。
在某些实施方案中，能够用于本公开的胰岛素增敏剂(insulin sensitizer)的示例性实例包括但不限于罗格列酮(rosiglitazone)和吡格列酮(pioglitazone)。
在某些实施方案中，本公开的片芯包含第三活性药物成分。
在某些实施方案中，能够用于本公开的第三活性药物成分的示例性实例包括但不限于二肽基肽酶-4(dipeptidyle peptidase-4,DPP-4)抑制剂、钠-葡萄糖共转运体2(sodium/glucose cotranspoter 2,SGLT-2)抑制剂、磺酰脲类药物(sulfonylureas)、非磺酰脲类药物(non-sulfonylurea)、α-糖苷酶抑制剂(glucosidase inhibitor)和胰岛素增敏剂(insulin sensitizer)。
在某些实施方案中，能够用于本公开的二肽基肽酶-4(dipeptidyle peptidase-4,DPP-4)抑制剂的示例性实例包括但不限于西格列汀(sitagliptin)、维格列汀(vildagliptin)、沙格列汀(saxagliptin)、阿格列汀 (alogliptin)、利格列汀(linagliptin)、吉格列汀(gemigliptin)和替格列汀。
在某些实施方案中，能够用于本公开的钠-葡萄糖共转运体2(sodium/glucose cotranspoter 2,SGLT-2)抑制剂的示例性实例包括但不限于托格列净(tofogliflozin)、恩格列净(empagliflozin)、依格列净L-脯氨酸(ipragliflozin L-proline)、鲁格列净(luseogliflozin)、达格列净丙二醇(dapagliflozin propanediol)、卡格列净(canagliflozin)、埃格列净(ertugliflozin)。
在某些实施方案中，能够本公开的磺酰脲类药物(sulfonylureas)的示例性实例包括但不限于：格列吡嗪(glipizide)、格列齐特(gliclazide)、格列本脲(glibenclamide)、格列波脲(glibornuride)、格列美脲(glimepiride)和格列喹酮(gliquidone)。
在某些实施方案中，能够用于本公开的非磺酰脲类药物(non-sulfonylureas)的示例性实例包括但不限于瑞格列奈(repaglinide)和那格列奈(nateglinide)。
在某些实施方案中，能够用于本公开的α-糖苷酶抑制剂(glucosidase inhibitor)的示例性实例包括但不限于阿卡波糖(acarbose)和伏格列波糖(voglibose)。
在某些实施方案中，能够用于本公开的胰岛素增敏剂(insulin sensitizer)的示例性实例包括但不限于罗格列酮(rosiglitazone)和吡格列酮(pioglitazone)。
在某些实施方案中，本公开的胃滞留片包含在缓释层外的第二包衣层。
在某些实施方案中，本公开的第二包衣层包含水溶性聚合物。
在某些实施方案中，能够用于本公开的第二包衣层的水溶性聚合物的示例性实例包括但不限于海藻酸钠、羟丙甲纤维素、聚乙烯醇、聚乙烯醇-聚乙二醇接枝聚合物以及包含聚乙二醇和聚乙烯醇的混合物。
在某些实施方案中，能够用于本公开的第二包衣层的水溶性聚合物的示例性实例包括但不限于海藻酸钠、羟丙甲纤维素、聚乙烯醇、聚乙烯醇-聚乙二醇接枝聚合物以及包含聚乙二醇和聚乙烯醇的混合 物。
在某些实施方案中，能够用于本公开的包含聚乙二醇和聚乙烯醇的混合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000017
II。
在某些实施方案中，能够用于本公开的聚乙烯醇-聚乙二醇接枝聚合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000018
IR。
在某些实施方案中，本公开的胃滞留片包含在片芯和缓释层之间的隔离层、在缓释层外的第一包衣层以及在第一包衣层外的第二包衣层。
在某些实施方案中，本公开的胃滞留片的片芯还包含填充剂。
在某些实施方案中，能够用于本公开的填充剂的示例性实例包括但不限于乳糖、葡萄糖、蔗糖、木糖醇、甘露醇、山梨醇、麦芽糊精、糖粉、糊精类、微晶纤维素、无机盐类、甘露醇和淀粉。
在某些实施方案中，本公开的胃滞留片的片芯还包含助流剂。
在某些实施方案中，能够用于本公开的片芯中的助流剂的示例性实例包括但不限于胶态二氧化硅、微粉硅胶、聚乙二醇、硬脂酸镁、硬脂酸、滑石粉和淀粉。
在某些实施方案中，本公开的胃滞留片的片芯还包含粘合剂。
在某些实施方案中，能够用于本公开的片芯中的粘合剂的示例性实例包括但不限于聚乙烯醇、羧甲基纤维素钠、淀粉桨类、聚维酮、共聚维酮、蔗糖溶液、羟丙甲纤维素、羟丙基纤维素、甲基羟乙基纤维素、羟乙基纤维素、甲基纤维素、麦芽糊精、淀粉、羧甲基淀粉钠、预胶化淀粉、羟丙基纤维素、羧甲基淀粉钠、明胶、阿拉伯胶、瓜尔胶、槐豆胶、罗望子多糖胶、田菁胶、亚麻籽胶、皂荚糖胶、果胶、黄蜀葵胶、卡拉胶、琼脂、海藻酸钠、海藻酸钾、明胶、甲壳素、黄原胶、β-环状糊精、聚葡萄糖、结冷胶和丙烯酸树脂。
在某些实施方案中，本公开的胃滞留片的片芯还包含润滑剂。
在某些实施方案中，能够用于本公开的片芯中的润滑剂的示例性实例包括但不限于山嵛酸甘油酯、脂肪酸及其金属皂类、酯类、氢化植物油、聚乙二醇类和月桂醇硫酸镁。
在某些实施方案中，能够用于本公开的脂肪酸及其金属皂类的示 例性实例包括但不限于硬脂酸镁、硬脂酸、硬脂酸锌、硬脂酸钙、硬脂酸铅、硬脂酸钡和硬质富马酸钠。
在某些实施方案中，能够用于本公开的酯类的示例性实例包括但不限于山嵛酸甘油酯、三硬脂酸甘油酯、硬脂酸单甘油酯和硬脂酸丁酯。
在某些实施方案中，本公开的胃滞留片的片芯为单层。
在某些实施方案中，本公开的胃滞留片的片芯为双层。
在某些实施方案中，本公开的胃滞留片的片芯为三层。
在某些实施方案中，本公开的胃滞留片的片芯为单室。
在某些实施方案中，本公开的胃滞留片的片芯为双室。
在某些实施方案中，本公开的胃滞留片的片芯为三室。
在某些实施方案中，本公开的胃滞留片的片芯的硬度约为5至15kp。
在某些实施方案中，本公开的胃滞留片在水性介质中能够在10分钟内起漂。
在某些实施方案中，本公开的胃滞留片在水性介质中能够立即起漂。
在某些实施方案中，本公开的胃滞留片的短径不大于约9mm，其厚度不大于短径。
在某些实施方案中，本公开的胃滞留片的片重不大于约800mg。
在某些实施方案中，本公开的胃滞留片在水性介质中膨胀后的短径不小于约11mm。
在某些实施方案中，本公开的胃滞留片在水性介质中膨胀后，缓释层包衣具有良好的张力。
另一方面，本公开涉及制备胃滞留片的方法，其包括：
制备含有第一活性药物成分和膨胀剂的片芯；
对所述片芯进行隔离层包衣，从而得到具有隔离层的片，以及
对所述具有隔离层的片进行缓释层包衣，从而得到所述胃滞留片。
在某些实施方案中，本公开的方法还包括在进行缓释层包衣后进行第一包衣，从而得到第一包衣层。
在某些实施方案中，本公开的第一包衣层包含水溶性聚合物。
在某些实施方案中，能够用于本公开的第一包衣层的水溶性聚合物的示例性实例包括但不限于包含聚乙二醇和聚乙烯醇的混合物、海藻酸钠、羟丙甲纤维素、聚乙烯醇和聚乙烯醇-聚乙二醇接枝聚合物。
在某些实施方案中，能够用于本公开的第一包衣层的水溶性聚合物的示例性实例包括但不限于包含聚乙二醇和聚乙烯醇的混合物和聚乙烯醇-聚乙二醇接枝聚合物。
在某些实施方案中，能够用于本公开的包含聚乙二醇和聚乙烯醇的混合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000019
II。
在某些实施方案中，能够用于本公开的聚乙烯醇-聚乙二醇接枝聚合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000020
IR。
在某些实施方案中，本公开的第一包衣层含有第二活性药物成分。
在某些实施方案中，能够用于公开的第二活性药物成分的示例性实例包括但不限于二肽基肽酶-4(dipeptidyle peptidase-4,DPP-4)抑制剂、钠-葡萄糖共转运体2(sodium/glucose cotransporter 2,SGLT-2)抑制剂、磺酰脲类药物(sulfonylureas)、非磺酰脲类药物(non-sulfonylureas)、α-糖苷酶抑制剂(glucosidase inhibitor)、胰岛素增敏剂(insulin sensitizer)。
在某些实施方案中，能够用于本公开的二肽基肽酶-4(dipeptidyle peptidase-4,DPP-4)抑制剂的示例性实例包括但不限于西格列汀(sitagliptin)、维格列汀(vildagliptin)、沙格列汀(saxagliptin)、阿格列汀(alogliptin)、利格列汀(linagliptin)、吉格列汀(gemigliptin)和替格列汀。
在某些实施方案中，能够用于本公开的钠-葡萄糖共转运体2(sodium/glucose cotranspoter 2,SGLT-2)抑制剂的示例性实例包括但不限于托格列净(tofogliflozin)、恩格列净(empagliflozin)、依格列净L-脯氨酸(ipragliflozin L-proline)、鲁格列净(luseogliflozin)、达格列净丙二醇(dapagliflozin propanediol)、卡格列净(canagliflozin)、埃格列净(ertugliflozin)。
在某些实施方案中，能够本公开的磺酰脲类药物(sulfonylureas)的示例性实例包括但不限于：格列吡嗪(glipizide)、格列齐特(gliclazide)、 格列本脲(glibenclamide)、格列波脲(glibornuride)、格列美脲(glimepiride)和格列喹酮(gliquidone)。
在某些实施方案中，能够用于本公开的非磺酰脲类药物(non-sulfonylureas)的示例性实例包括但不限于瑞格列奈(repaglinide)和那格列奈(nateglinide)。
在某些实施方案中，能够用于本公开的α-糖苷酶抑制剂(glucosidase inhibitor)的示例性实例包括但不限于阿卡波糖(acarbose)和伏格列波糖(voglibose)。
在某些实施方案中，能够用于本公开的胰岛素增敏剂(insulin sensitizer)的示例性实例包括但不限于罗格列酮(rosiglitazone)和吡格列酮(pioglitazone)。
在某些实施方案中，本公开的片芯包含第三活性药物成分。
在某些实施方案中，能够用于本公开的第三活性药物成分的示例性实例包括但不限于二肽基肽酶-4(dipeptidyle peptidase-4,DPP-4)抑制剂、钠-葡萄糖共转运体2(sodium/glucose cotranspoter 2,SGLT-2)抑制剂、磺酰脲类药物(sulfonylureas)、非磺酰脲类药物(non-sulfonylurea)、α-糖苷酶抑制剂(glucosidase inhibitor)和胰岛素增敏剂(insulin sensitizer)。
在某些实施方案中，能够用于本公开的二肽基肽酶-4(dipeptidyle peptidase-4,DPP-4)抑制剂的示例性实例包括但不限于西格列汀(sitagliptin)、维格列汀(vildagliptin)、沙格列汀(saxagliptin)、阿格列汀(alogliptin)、利格列汀(linagliptin)、吉格列汀(gemigliptin)和替格列汀。
在某些实施方案中，能够用于本公开的钠-葡萄糖共转运体2(sodium/glucose cotranspoter 2,SGLT-2)抑制剂的示例性实例包括但不限于托格列净(tofogliflozin)、恩格列净(empagliflozin)、依格列净L-脯氨酸(ipragliflozin L-proline)、鲁格列净(luseogliflozin)、达格列净丙二醇(dapagliflozin propanediol)、卡格列净(canagliflozin)、埃格列净(ertugliflozin)。
在某些实施方案中，能够本公开的磺酰脲类药物(sulfonylureas)的示例性实例包括但不限于：格列吡嗪(glipizide)、格列齐特(gliclazide)、 格列本脲(glibenclamide)、格列波脲(glibornuride)、格列美脲(glimepiride)和格列喹酮(gliquidone)。
在某些实施方案中，能够用于本公开的非磺酰脲类药物(non-sulfonylureas)的示例性实例包括但不限于瑞格列奈(repaglinide)和那格列奈(nateglinide)。
在某些实施方案中，能够用于本公开的α-糖苷酶抑制剂(glucosidase inhibitor)的示例性实例包括但不限于阿卡波糖(acarbose)和伏格列波糖(voglibose)。
在某些实施方案中，能够用于本公开的胰岛素增敏剂(insulin sensitizer)的示例性实例包括但不限于罗格列酮(rosiglitazone)和吡格列酮(pioglitazone)。
在某些实施方案中，本公开的胃滞留片包含在缓释层外的第二包衣层。
在某些实施方案中，本公开的第二包衣层含有水溶性聚合物。
在某些实施方案中，能够用于本公开的第二包衣层的水溶性聚合物的示例性实例包括但不限于海藻酸钠、羟丙甲纤维素、聚乙烯醇、聚乙烯醇-聚乙二醇接枝聚合物以及包含聚乙二醇和聚乙烯醇的混合物。
在某些实施方案中，能够用于本公开的第二包衣层的水溶性聚合物的示例性实例包括但不限于海藻酸钠、羟丙甲纤维素、聚乙烯醇、聚乙烯醇-聚乙二醇接枝聚合物以及包含聚乙二醇和聚乙烯醇的混合物。
在某些实施方案中，能够用于本公开的包含聚乙二醇和聚乙烯醇的混合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000021
II。
在某些实施方案中，能够用于本公开的聚乙烯醇-聚乙二醇接枝聚合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000022
IR。
在某些实施方案中，能够用于本公开的膨胀剂的示例性实例包括但不限于羧甲淀粉钠、预胶化淀粉、交联羧甲基纤维素钠、交联羧甲基纤维素钙和低取代羟丙基纤维素。
在某些实施方案，本公开的胃滞留片中的缓释层含有包含聚醋酸 乙烯酯和聚维酮的混合物。
在某些实施方案，本公开的胃滞留片中的缓释层含有丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物。
在某些实施方案，本公开的胃滞留片中的缓释层含有包含聚醋酸乙烯酯和聚维酮的混合物与丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物。
在某些实施方案中，能能够用于本公开的包含聚醋酸乙烯酯和聚维酮的混合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000023
SR。
在某些实施方案中，能能够用于本公开的丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物的示例性实例包括但不限于
Figure PCTCN2020142069-appb-000024
NE 30D。
在某些实施方案中，本公开的胃滞留片中的缓释层中包含聚醋酸乙烯酯和聚维酮的混合物与丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物的重量比约为1:20至20:1。
在某些实施方案中，制备包含二甲双胍或其药物可接受的盐的颗粒的方法包括但不限于使用流化床制粒。
在某些实施方案中，能够用于本公开的制备包含二甲双胍或其药物可接受的盐的颗粒的方法的示例性实例包括但不限于湿法制粒和干法制粒。
在某些实施方案中，能够用于本公开的湿法制粒的实例包括但不限于流化床制粒、湿法制粒机制粒和手工湿法制粒。
在某些实施方案中，能够用于本公开的干法制粒的示例性实例包括但不限于干法制粒机制粒。
再一方面，本公开涉及胃滞留片，其由包括如下步骤的方法制备得到，制备含有第一活性药物成分和膨胀剂的片芯；
对所述片芯进行隔离层包衣，从而得到具有隔离层的片，以及
对所述具有隔离层的片进行缓释层包衣，从而得到所述胃滞留片。
在某些实施方案中，本公开的方法还包括在进行缓释层包衣后进行第一包衣，从而得到具有第一包衣层的片。
在某些实施方案中，本公开的第一包衣层包含水溶性聚合物。
在某些实施方案中，本公开的第一包衣层含有第二活性药物成分。
在某些实施方案中，本公开的胃滞留片包含在进行缓释层包衣后进行第二包衣，从而得到具有第二包衣层的片。
在某些实施方案中，本公开的第二包衣层包含水溶性聚合物。
在某些实施方案中，本公开的胃滞留片的片芯为单层。
在某些实施方案中，本公开的胃滞留片的片芯为双层。
在某些实施方案中，本公开的胃滞留片的片芯为三层。
在某些实施方案中，本公开的胃滞留片的片芯为单室。
在某些实施方案中，本公开的胃滞留片的片芯为双室。
在某些实施方案中，本公开的胃滞留片的片芯为三室。
在某些实施方案中，本公开的胃滞留片的片芯的硬度约为5至15kp。
在某些实施方案中，本公开的胃滞留片在水性介质中能够在10分钟内起漂。
在某些实施方案中，本公开的胃滞留片在水性介质中能够立即起漂。
在某些实施方案中，本公开的胃滞留片的短径不大于约9mm，其厚度不大于短径。
在某些实施方案中，本公开的胃滞留片的片重不大于约800mg。
在某些实施方案中，本公开的胃滞留片在水性介质中膨胀后的短径不小于约11mm。
在某些实施方案中，本公开的胃滞留片在水性介质中膨胀后，缓释层包衣具有良好的张力。
又一方面，本公开涉及改善个体的顺应性的方法，其包括向需要所述方法的所述个体给予胃滞留片，其中所述胃滞留片包含片芯、缓释层以及在所述片芯和所述缓释层之间的隔离层，其中所述片芯含有第一活性药物成分和膨胀剂。
在某些实施方案中，本公开的胃滞留片包含在缓释层外的第一包衣层。
在某些实施方案中，本公开的第一包衣层包含水溶性聚合物。
在某些实施方案中，本公开的第一包衣层含有第二活性药物成分。
在某些实施方案中，本公开的胃滞留片包含在缓释层外的第二包衣层。
在某些实施方案中，本公开的第二包衣层包含水溶性聚合物。
在某些实施方案中，能够用于本公开的个体的示例性实例包括但不限于哺乳动物。
在某些实施方案中，能够用于本公开的哺乳动物的示例性实例包括但不限于狗、猫、牛、羊、马和人类。
在某些实施方案中，哺乳动物是人类。
下文中，本公开将通过如下实施例进行详细解释以便更好地理解本申请的各个方面及其优点。然而，应当理解，以下的实施例是非限制性的而且仅用于说明本公开的某些实施方案。
实施例
本公开的实施例中使用的试剂和设备均为常规的并且可商购的。例如：
表1原辅料来源
Figure PCTCN2020142069-appb-000025
Figure PCTCN2020142069-appb-000026
表2实验主要仪器设备
Figure PCTCN2020142069-appb-000027
实施例1
500mg盐酸二甲双胍缓释片
(1)制粒
称取处方量的聚醋酸乙烯酯(polyvinyl acetate,PVA)，用纯化水配制成4％的溶液，称取过30目筛的盐酸二甲双胍，至于流化床中，加入处方量的胶态二氧化硅和羧甲淀粉钠，采用顶喷制粒的方式制备盐酸二甲双胍颗粒，流化床物料温度控制在35至45℃。
(2)混合、压片
将制备的盐酸二甲双胍颗粒与处方量胶态二氧化硅混合40转，加入处方量交联聚维酮，混合100分钟，最后加入处方量山嵛酸甘油酯，润滑50转，压片。处方如表3。
(3)隔离层包衣
称取隔离层辅料分散或溶解至纯水中，搅拌至均匀作为隔离层包衣液。隔离层包衣过程中，控制物料温度为30至45℃，包衣增重1至5％。
(4)缓释层包衣
称取缓释层辅料分散或溶解至纯水中，搅拌至均匀作为缓释层包衣液。缓释层包衣过程中，控制物料温度为30至45℃，包衣增重5至15％。
表3.盐酸二甲双胍缓释片处方
Figure PCTCN2020142069-appb-000028
Figure PCTCN2020142069-appb-000029
实施例2
500mg盐酸二甲双胍缓释片
(1)制粒
称取处方量的聚醋酸乙烯酯(polyvinyl acetate,PVA)，用纯化水配制成4％的溶液，称取过30目筛的盐酸二甲双胍，至于流化床中，加入处方量的胶态二氧化硅和羧甲淀粉钠，采用顶喷制粒的方式制备盐酸二甲双胍颗粒，流化床物料温度控制在35至45℃。
(2)混合、压片
将制备的盐酸二甲双胍颗粒与处方量胶态二氧化硅混合40转，加入处方量交联聚维酮，混合100分钟，最后加入处方量山嵛酸甘油酯，润滑50转，压片。处方如表3。
(3)隔离层包衣
称取隔离层辅料分散或溶解至纯水中，搅拌至均匀作为隔离层包衣液。隔离层包衣过程中，控制物料温度为30至45℃，包衣增重1至5％。
(4)缓释层包衣
称取缓释层辅料分散或溶解至纯水中，搅拌至均匀作为缓释层包衣液。缓释层包衣过程中，控制物料温度为30至45℃，包衣增重5至15％。
表4.盐酸二甲双胍缓释片处方
Figure PCTCN2020142069-appb-000030
实施例3
500mg盐酸二甲双胍缓释片
(1)制粒
称取处方量的聚醋酸乙烯酯(polyvinyl acetate,PVA)，用纯化水配制成4％的溶液，称取过30目筛的盐酸二甲双胍，至于流化床中，加入处方量的胶态二氧化硅和羧甲淀粉钠，采用顶喷制粒的方式制备盐酸二甲双胍颗粒，流化床物料温度控制在35至45℃。
(2)混合、压片
将制备的盐酸二甲双胍颗粒与处方量胶态二氧化硅混合40转，加入处方量交联聚维酮，混合100分钟，最后加入处方量山嵛酸甘油酯，润滑50转，压片。处方如表3。
(3)隔离层包衣
称取隔离层辅料分散或溶解至纯水中，搅拌至均匀作为隔离层包衣液。隔离层包衣过程中，控制物料温度为30至45℃，包衣增重1至5％。
(4)缓释层包衣
称取缓释层辅料分散或溶解至纯水中，搅拌至均匀作为缓释层包衣液。缓释层包衣过程中，控制物料温度为30至45℃，包衣增重5至15％。
表5.盐酸二甲双胍缓释片处方
Figure PCTCN2020142069-appb-000031
Figure PCTCN2020142069-appb-000032
实施例4
500mg盐酸二甲双胍缓释片
(1)制粒
称取处方量的聚醋酸乙烯酯(polyvinyl acetate,PVA)，用纯化水配制成4％的溶液，称取过30目筛的盐酸二甲双胍，至于流化床中，加入处方量的胶态二氧化硅和羧甲淀粉钠，采用顶喷制粒的方式制备盐酸二甲双胍颗粒，流化床物料温度控制在35至45℃。
(2)混合、压片
将制备的盐酸二甲双胍颗粒与处方量胶态二氧化硅混合40转，加入处方量交联聚维酮，混合100分钟，最后加入处方量山嵛酸甘油酯，润滑50转，压片。处方如表3。
(3)隔离层包衣
称取隔离层辅料分散或溶解至纯水中，搅拌至均匀作为隔离层包衣液。隔离层包衣过程中，控制物料温度为30至45℃，包衣增重1至5％。
(4)缓释层包衣
称取缓释层辅料分散或溶解至纯水中，搅拌至均匀作为缓释层包衣液。缓释层包衣过程中，控制物料温度为30至45℃，包衣增重5 至15％。
表6.盐酸二甲双胍缓释片处方
Figure PCTCN2020142069-appb-000033
实施例5
盐酸二甲双胍缓释片释放度测定
待测样品：
实施例1到4制备得到的盐酸二甲双胍缓释片；
实施例1样品设置3个平行样；
实施例2样品设置3个平行样；
实施例3样品设置6个平行样；
实施例4样品设置3个平行样。
释放度实验采用Sotax溶出仪和岛津紫外分光光度计测定。
释放度测定
参考FDA、《美国药典》和《中国药典》的盐酸二甲双胍缓释片的释放度检测方法，以及《普通口服固体制剂溶出度试验技术指导原则》，建立样品释放度测定方法：转速200rpm，水浴温度(37.0±0.5)℃，溶出介质为pH 1.2盐酸溶液，介质体积1000mL。
溶出介质pH 1.2盐酸溶液配制方法：量取浓盐酸53.55mL，加水稀释至7000mL，混合均匀，即得pH 1.2盐酸溶液。
将待测样品置于溶出仪转篮中，分别于1h，2h，4h，6h，8h，10h，12h，14h和16h取样9mL，用0.45μm微孔滤膜过滤，取滤液用紫外分光光度计测定吸光度。分别计算盐酸二甲双胍在不同释放时间的累积释放度，如表6至19所示。
表7.实施例1的二甲双胍缓释片释放度结果
时间/h 片1 片2 片3 平均值 RSD(％)
0 0.00 0.00 0.00 0.00 0.00
1 8.50 6.99 7.38 7.62 10.24
2 20.87 18.95 19.11 19.64 5.41
4 41.09 37.45 37.01 38.52 5.81
6 60.63 54.15 53.04 55.94 7.33
8 74.08 69.11 67.68 70.29 4.78
10 83.99 79.78 78.66 80.81 3.47
12 89.30 86.68 85.51 87.16 2.22
14 91.98 90.82 90.11 90.97 1.03
16 93.73 93.28 92.48 93.16 0.68
表8.实施例2的二甲双胍缓释片释放度结果
时间/h 片1 片2 片3 平均值 RSD(％)
0 0.00 0.00 0.00 0.00 0.00
1 8.80 6.96 7.42 7.73 12.39
2 20.87 16.92 18.50 18.76 10.59
4 47.76 41.99 42.11 43.95 7.50
6 67.26 61.89 61.66 63.61 4.98
8 79.91 75.65 75.43 77.00 3.28
10 87.00 84.72 84.61 85.44 1.58
12 92.46 90.86 90.54 91.28 1.13
14 94.65 94.08 93.96 94.23 0.39
16 95.81 95.72 95.83 95.78 0.06
表9.实施例3的二甲双胍缓释片释放度结果
时间/h 片1 片2 片3 片4 片5 片6 平均值 RSD(％)
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 4.88 8.40 6.65 7.22 7.57 6.30 6.84 17.65
2 19.18 29.05 23.22 23.86 23.80 18.03 22.86 17.19
4 49.68 58.41 52.24 52.56 53.64 42.31 51.47 10.35
6 68.41 75.38 70.87 70.58 72.57 61.79 69.93 6.60
8 81.26 85.69 83.00 82.29 83.92 75.53 81.95 4.25
10 88.78 91.40 89.85 89.40 90.51 84.65 89.10 2.65
12 93.26 94.06 93.65 93.12 93.66 90.45 93.03 1.41
14 95.51 95.51 95.57 94.95 95.25 93.59 95.06 0.80
16 96.67 96.09 96.26 95.81 95.89 95.08 95.97 0.55
表10.实施例4的二甲双胍缓释片释放度结果
时间/h 片1 片2 片3 平均值 RSD(％)
0 0.00 0.00 0.00 0.00 0.00
1 4.49 4.91 5.93 5.11 14.48
2 12.60 12.44 13.35 12.80 3.82
4 28.07 29.80 30.50 29.46 4.25
6 45.56 47.51 47.89 46.99 2.67
8 59.32 61.34 61.33 60.67 1.92
10 69.78 71.62 71.43 70.94 1.43
12 77.47 79.33 78.92 78.58 1.24
14 82.88 84.68 84.45 84.00 1.17
16 87.18 88.29 87.96 87.81 0.65
在本公开中，诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来，而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。
从前述中可以理解，尽管为了示例性说明的目的描述了本公开的具体实施方案，但是在不偏离本公开的精神和范围的条件下，本领域所述技术人员可以作出各种变形或改进。这些变形或修改都应落入本公开所附权利要求的范围。

Claims (18)

  1. 胃滞留片，其包含片芯、缓释层以及在所述片芯和所述缓释层之间的隔离层，其中所述片芯含有第一活性药物成分和膨胀剂。
  2. 如权利要求2所述的胃滞留片，其中所述隔离层包含水溶性聚合物，优选所述水性聚合物选自海藻酸钠、羟丙甲纤维素、聚乙烯醇、聚乙烯醇-聚乙二醇接枝聚合物、包含聚乙二醇和聚乙烯醇的混合物及其混合物，更优选聚乙烯醇-聚乙二醇接枝聚合物。
  3. 如权利要求1或2所述的胃滞留片，其中所述第一活性药物成分选自左旋多巴、盐酸甲氨二氮卓、地西泮、呋喃苯胺酸、卡托普利、琥珀酸美托洛尔、马来酸罗格列酮、维拉帕米、阿替洛尔、氯沙坦、己酮可可碱、尼莫地平、桂利嗪、地尔硫卓、吡咯他尼、硝酸异山梨酯、索他洛尔、普萘洛尔、盐酸塞利洛尔、消胆胺、硝苯地平、双嘧达莫、葡萄糖酸奎尼丁、洛伐他汀、盐酸曲美他嗪、尼卡地平、单硝酸异山梨酯、甲硝唑、克拉霉素、呋喃妥因、氧氟沙星、头孢氨苄、齐多夫定、环丙沙星、灰黄霉素、氨苄西林、酮洛芬、布洛芬、吡罗昔康、氟比洛芬、吲哚美辛、双氯芬酸钠、马来酸氯苯那敏、茶碱、氟尿嘧啶、核黄素-5’-磷酸钠、米索前列醇、熊去氧胆酸、牛磺熊去氧胆酸、胃酶抑素、曲尼司特、特非那定、奥利司他、阿苯达唑、氢化泼尼松、氯雷他定、卡比多巴与左旋多巴、左旋多巴与苄丝肼、普瑞巴林、盐酸二甲双胍、阿莫西林、阿昔洛韦和加巴喷丁，优选卡比多巴与左旋多巴、左旋多巴与苄丝肼、普瑞巴林、盐酸二甲双胍、阿莫西林、阿昔洛韦和加巴喷丁。
  4. 如权利要求1至3中任一权利要求所述的片剂，其中所述缓释层包含致孔剂，优选所述致孔剂为水溶性聚合物，更优选选自海藻酸钠、羟丙甲纤维素、羟丙基纤维素、聚维酮、聚乙二醇、聚乙烯醇及其混合物，甚至更优选自羟丙甲纤维素、羟丙基纤维素、聚维酮、聚乙二醇及其混合物。
  5. 如权利要求1至4中任一权利要求所述的胃滞留片，其中所述的膨胀剂选自交联聚维酮、羧甲基淀粉钠、预胶化淀粉、交联羧甲基纤维素钠、交联羧甲基纤维素钙、低取代羟丙基纤维素及其混合物。
  6. 如权利要求1至5中任一权利要求所述的胃滞留片，其中所述片芯包含粘合剂，优选所述粘合剂选自聚乙烯醇、羟丙甲纤维素、聚维酮及其混合物。
  7. 如权利要求1至6中任一权利要求所述的胃滞留片，其中所述片剂包含在所述缓释层外的第一包衣层，优选所述第一包衣层包含水溶性聚合物，优选所述水性聚合物选自海藻酸钠、羟丙甲纤维素、聚乙烯醇、包含聚乙二醇和聚乙烯醇的混合物、聚乙烯醇-聚乙二醇接枝聚合物及其混合物，更优选包含聚乙二醇和聚乙烯醇的混合物、聚乙烯醇-聚乙二醇接枝聚合物及其混合物。
  8. 如权利要求7所述的胃滞留片，其中所述第一包衣层含有第二活性药物成分，优选所述第二活性药物成分选自二肽基肽酶-4(dipeptidyle peptidase-4,DPP-4)抑制剂、钠-葡萄糖共转运体2(sodium/glucose cotransporter 2,SGLT-2)抑制剂、磺酰脲类药物(sulfonylureas)、非磺酰脲类药物(non-sulfonylureas)、α-糖苷酶抑制剂(glucosidase inhibitor)、胰岛素增敏剂(insulin sensitizer)及其混合物。
  9. 如权利要求1至8中任一权利要求所述的胃滞留片，其中所述胃滞留片包含在所述缓释层外的第二包衣层，优选所述第二包衣层包含水溶性聚合物，优选所述水溶性聚合物选自羟丙甲纤维素、聚乙烯醇、聚乙烯醇-聚乙二醇接枝聚合物、包含聚乙二醇和聚乙烯醇的混合物及其混合物，更优选包含聚乙二醇和聚乙烯醇的混合物、聚乙烯醇-聚乙二醇接枝聚合物及其混合物。
  10. 如权利要求1至9中任一权利要求所述的胃滞留片，其在水性介质中膨胀后的短径不小于11mm。
  11. 制备胃滞留片的方法，其包括：
    制备含有第一活性药物成分和膨胀剂的片芯；
    对所述片芯进行隔离层包衣，从而得到具有隔离层的片，以及
    对所述具有隔离层的片进行缓释层包衣，从而得到所述胃滞留片。
  12. 如权利要求11所述的方法，还包括在进行所述缓释层包衣后进行第一包衣，从而得到第一包衣层，优选所述第一包衣层含有第二活性药物成分，更优选所述第二活性药物成分选自二肽基肽酶-4(dipeptidyle peptidase-4,DPP-4)抑制剂、钠-葡萄糖共转运体2(sodium/glucose cotransporter 2,SGLT-2)抑制剂、磺酰脲类药物(sulfonylureas)、非磺酰脲类药物(non-sulfonylureas)、α-糖苷酶抑制剂(glucosidase inhibitor)、胰岛素增敏剂(insulin sensitizer)及其混合物。
  13. 如权利要求11或12所述的方法，还包括在进行所述缓释层包衣后进行第二包衣，从而得到第二包衣层。
  14. 如权利要求11至13中任一权利要求所述的方法，其中所述膨胀剂选自羧甲淀粉钠、预胶化淀粉、交联羧甲基纤维素钠、交联羧甲基纤维素钙、低取代羟丙基纤维素及其混合物。
  15. 如权利要求11至14中任一权利要求所述的方法，所述缓释层含有包含聚醋酸乙烯酯和聚维酮的混合物、丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物、或者包含聚醋酸乙烯酯和聚维酮的混合物与丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物的混合物，优选包含聚醋酸乙烯酯和聚维酮的混合物、丙烯酸乙酯和甲基丙烯酸甲酯单体的聚合物或其混合物。
  16. 由权利要求11至15中任一权利要求所述的方法制备得到的胃滞留片。
  17. 如权利要求16所述的胃滞留片，其在水性介质中膨胀后的短径不小于11mm。
  18. 改善个体的顺应性的方法，其包括向需要所述方法的所述个体给予权利要求1至10、16和17中任一权利要求所述的胃滞留片。
PCT/CN2020/142069 2019-12-31 2020-12-31 胃滞留片 WO2021136492A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201911419357.2 2019-12-31
CN201911410594.2 2019-12-31
CN201911419340.7 2019-12-31
CN201911419357 2019-12-31
CN201911410594 2019-12-31
CN201911419340 2019-12-31

Publications (1)

Publication Number Publication Date
WO2021136492A1 true WO2021136492A1 (zh) 2021-07-08

Family

ID=76685859

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2020/142069 WO2021136492A1 (zh) 2019-12-31 2020-12-31 胃滞留片
PCT/CN2020/142074 WO2021136494A1 (zh) 2019-12-31 2020-12-31 胃滞留片

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/142074 WO2021136494A1 (zh) 2019-12-31 2020-12-31 胃滞留片

Country Status (2)

Country Link
CN (9) CN113116847B (zh)
WO (2) WO2021136492A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960711A (zh) * 2004-03-25 2007-05-09 太阳医药工业有限公司 胃内滞留系统
CA2576556A1 (en) * 2007-02-01 2008-08-01 Isa Odidi Drug delivery device
CN104220049A (zh) * 2012-03-07 2014-12-17 勃林格殷格翰国际有限公司 包含二甲双胍和dpp-4抑制剂或sglt-2抑制剂的药物组合物
CN107205969A (zh) * 2014-12-23 2017-09-26 韩德株式会社 糖尿病治疗用药物组合物
CA3031412A1 (en) * 2017-06-16 2018-12-20 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
WO2019129171A1 (zh) * 2017-12-29 2019-07-04 江苏恒瑞医药股份有限公司 一种控释药物组合物及其制备方法
US20190374473A1 (en) * 2017-06-16 2019-12-12 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721493C (en) * 2008-04-18 2017-11-28 Intec Pharma Ltd. Carbidopa/levodopa gastroretentive drug delivery
US20110287096A1 (en) * 2010-05-18 2011-11-24 Abon Pharmaceuticals, Llc Modified gastroretentive drug delivery system for amine drugs
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
CN105326813B (zh) * 2014-07-22 2019-04-09 广州玻思韬控释药业有限公司 帕罗西汀缓释组合物及其制备方法
KR101642193B1 (ko) * 2014-10-13 2016-07-25 씨제이헬스케어 주식회사 메트포르민 서방성 제제 및 그의 제조방법
CN107184560B (zh) * 2017-06-03 2021-02-02 寿光富康制药有限公司 二甲双胍胃滞留片及制备方法
US10588863B2 (en) * 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CN108159011A (zh) * 2018-03-16 2018-06-15 中国药科大学 一种双相控释的普瑞巴林胃滞留缓释片及其制备方法
CN108478537A (zh) * 2018-05-03 2018-09-04 南京易亨制药有限公司 一种含普瑞巴林的单室渗透泵控释片剂
EP3609472B1 (en) * 2018-06-18 2020-12-30 Kashiv Specialty Pharmaceuticals, LLC Extended release compositions comprising pyridostigmine
CN109044981B (zh) * 2018-08-07 2021-02-19 广州帝奇医药技术有限公司 一种普瑞巴林胃漂浮型缓释片及其制备方法
CN108969501A (zh) * 2018-08-20 2018-12-11 奕利制药有限公司 一种盐酸二甲双胍胃漂浮缓释片及其制备方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960711A (zh) * 2004-03-25 2007-05-09 太阳医药工业有限公司 胃内滞留系统
CA2576556A1 (en) * 2007-02-01 2008-08-01 Isa Odidi Drug delivery device
CN104220049A (zh) * 2012-03-07 2014-12-17 勃林格殷格翰国际有限公司 包含二甲双胍和dpp-4抑制剂或sglt-2抑制剂的药物组合物
CN107205969A (zh) * 2014-12-23 2017-09-26 韩德株式会社 糖尿病治疗用药物组合物
CA3031412A1 (en) * 2017-06-16 2018-12-20 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
US20190374473A1 (en) * 2017-06-16 2019-12-12 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
WO2019129171A1 (zh) * 2017-12-29 2019-07-04 江苏恒瑞医药股份有限公司 一种控释药物组合物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DESHPANDE ARATI A., NAVNIT H. SHAH, CHRISTOPHER T. RHODES, WASEEM MALICK: "Development of a Novel Controlled-Release System for Gastric Retention,", PHARMACEUTICAL RESEARCH, vol. 14, no. 6, 1 January 1997 (1997-01-01), pages 815 - 819, XP055825610 *

Also Published As

Publication number Publication date
CN113116839B (zh) 2024-02-06
CN113116841A (zh) 2021-07-16
CN113116844A (zh) 2021-07-16
CN113116846B (zh) 2024-03-19
CN113116845B (zh) 2024-03-19
CN113116845A (zh) 2021-07-16
CN113116851A (zh) 2021-07-16
CN113116847A (zh) 2021-07-16
CN113116846A (zh) 2021-07-16
CN113116847B (zh) 2024-03-29
CN113116850A (zh) 2021-07-16
CN113116839A (zh) 2021-07-16
CN113116850B (zh) 2024-03-19
CN113116842A (zh) 2021-07-16
WO2021136494A1 (zh) 2021-07-08

Similar Documents

Publication Publication Date Title
US20160271070A1 (en) Extended release suspension compositions
US20160228379A1 (en) Extended release suspension compositions
KR20190025947A (ko) 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제
EP3445349A1 (en) Extended release suspension compositions
BR112012024019B1 (pt) Forma de dosagem de liberação controlada para administração oral
ES2665775T3 (es) Comprimido recubierto con película que contiene alfoscerato de colina y proceso para su preparación
KR102078805B1 (ko) 토파시티닙을 포함하는 약제학적 조성물
ES2513415T3 (es) Composiciones farmacéuticas que comprenden un profármaco inhibidor de la polimerasa del VHC
TW201828932A (zh) 1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
ES2320265T3 (es) Formulaciones farmaceuticas de polimeros amino alifaticos y procedimientos para su preparacion.
WO2021136492A1 (zh) 胃滞留片
Krishna et al. Strategic Approaches and Evaluation of Gastro Retentive Drug Delivery system-A Review
BR112020025112A2 (pt) comprimido revestido por película e processo para a fabricação do comprimido revestido por película
WO2020111089A1 (ja) 医薬組成物
KR20210105761A (ko) 콜린알포세레이트를 주성분으로 하는 서방성 제제
WO2016001843A1 (en) Extended-release gastroretentive tablets of voglibose
CN1994283A (zh) 尼可地尔的缓释制剂
WO2019000101A1 (en) NEW FORMULATIONS USEFUL IN THE TREATMENT OF FOLATE DEFICIENCIES
ES2818249T3 (es) Composición farmacéutica que comprende un agente antipsicótico atípico y método para su preparación
WO2013051036A1 (en) Use of pharmaceutical composition for gastroretentive sustained and pulsatile drug delivery system
MX2007009916A (es) Composicion que comprende ocaperidona.
Pitta et al. Formulation and in vitro evaluation of tamsulosin hcl sustained release pellets in capsules
WO2013109226A1 (en) Pharmaceutical tablet formulations comprising cefuroxime
KR20230071725A (ko) 산 민감성 성분을 포함하는 삼투성 제제 조성물
CN101015528A (zh) 阿莫西林氟氯西林的缓释制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20910762

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20910762

Country of ref document: EP

Kind code of ref document: A1